Article Details
Retrieved on: 2025-04-27 20:43:43
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the epidemiology and market dynamics of atypical hemolytic uremic syndrome (aHUS), a rare blood disorder. It highlights increasing prevalence, significant pharmaceutical investments, and emerging therapies, including monoclonal antibodies like eculizumab and crovalimab. Key players include Alexion Pharmaceuticals, with a focus on the U.S. market.
Article found on: www.openpr.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here